Brief: Shaily Engineering Says Orbicular Pharma Launched Generic Of Semaglutide Injection In Canada, Incorporating Co’S Pen Platform
20/05/2026 11:31
May 20 (Reuters) - Shaily Engineering Plastics Ltd SEPL.NS: SHAILY ENGINEERING - ORBICULAR PHARMA LAUNCHED GENERIC OF SEMAGLUTIDE INJECTION IN CANADA, INCORPORATING CO’S PEN PLATFORM Source text: [ID:] Further company coverage: SEPL.NS ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shaily Engineering Plastics
See all newsIndia's Shaily Engineering rises after UBS notes likely gain from Zydus diabetes drug row
Brief: Shaily Engineering Says Orbicular Pharma Launched Generic Of Semaglutide Injection In Canada, Incorporating Co’S Pen Platform
India's Shaily Engineering rises on 4.23 billion-rupee order win
Brief: Shaily Engineering Plastics Gets Contract Worth About 4.23 Billion Rupees
India's Shaily Engineering rises as UBS initiates with 'buy' rating